Antihyperglycemic activity of the leaves from Annona cherimola miller and rutin on alloxan-induced diabetic rats

Fernando Calzada, Jesús Ivan Solares-Pascasio, R. M. Ordoñez-Razo, Claudia Velazquez, Elizabeth Barbosa, Normand García-Hernández, David Mendez-Luna, José Correa-Basurto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

© 2017 Pharmacognosy Research | Published by Wolters Kluwer - Medknow. Background: Annona cherimola, known as 'chirimoya' has been reported in Mexican traditional medicine for the treatment of diabetes. Objective: The aims of the present study were to validate and assess the traditional use of A. cherimola as an antidiabetic agent. Materials and Methods: The ethanol extract from A. cherimola (300 mg/kg, EEAc), subsequent fractions (100 mg/kg), and rutin (30 mg/kg) were studied on alloxan-induced type 2 diabetic (AITD) and normoglycemic rats. In addition, oral glucose tolerance test (OGTT) and oral sucrose tolerance test (OSTT) were performed in normoglycemic rats. Molecular docking technique was used to conduct the computational study. Results: Bioassay-guided fractionation of EEAc afforded as major antihyperglycemic compound, rutin. EEAc attenuated postprandial hyperglycemia in acute test using AITD rats (331.5 mg/dL) carrying the glycemic levels to 149.2 mg/dL. Rutin after 2 h, attenuated postprandial hyperglycemia in an acute assay using AITD rats such as EEAc, with maximum effect (150.0 mg/dL) being seen at 4 h. The antihyperglycemic activities of EEAc and rutin were comparable with acarbose (151.3 mg/dL). In the subchronic assay on AITD rats, the EEAc and rutin showed a reduction of the blood glucose levels since the 1 st week of treatment, reaching levels similar to normoglycemic state (116.9 mg/kg) that stayed constant for the rest of the assay. OGTT and OSTT showed that EEAc and rutin significantly lowered blood glucose levels in normoglycemic rats at 2 h after a glucose or sucrose load such as acarbose. Computational molecular docking showed that rutin interacted with four amino acids residues in the enzyme α-glucosidase. Conclusion: The results suggest that rutin an α-glucosidase inhibitor was responsible in part of the antihyperglycemic activity of A. cherimola. Its in vivo antihyperglycemic activity is in good agreement with the traditional use of A. cherimola for the treatment of diabetes.
Original languageAmerican English
Pages (from-to)1-6
Number of pages0
JournalPharmacognosy Research
DOIs
StatePublished - 1 Jan 2017

Fingerprint

Annona
Rutin
Alloxan
Hypoglycemic Agents
Rats
Glucose
Sugar (sucrose)
Assays
Acarbose
Medical problems
Glucosidases
Sucrose
Blood
Glucose Tolerance Test
Hyperglycemia
Blood Glucose
Pharmacognosy
Bioassay
Fractionation
Medicine

Cite this

Calzada, Fernando ; Solares-Pascasio, Jesús Ivan ; Ordoñez-Razo, R. M. ; Velazquez, Claudia ; Barbosa, Elizabeth ; García-Hernández, Normand ; Mendez-Luna, David ; Correa-Basurto, José. / Antihyperglycemic activity of the leaves from Annona cherimola miller and rutin on alloxan-induced diabetic rats. In: Pharmacognosy Research. 2017 ; pp. 1-6.
@article{9ac27c96548d43fdb89767bf7df49bf6,
title = "Antihyperglycemic activity of the leaves from Annona cherimola miller and rutin on alloxan-induced diabetic rats",
abstract = "{\circledC} 2017 Pharmacognosy Research | Published by Wolters Kluwer - Medknow. Background: Annona cherimola, known as 'chirimoya' has been reported in Mexican traditional medicine for the treatment of diabetes. Objective: The aims of the present study were to validate and assess the traditional use of A. cherimola as an antidiabetic agent. Materials and Methods: The ethanol extract from A. cherimola (300 mg/kg, EEAc), subsequent fractions (100 mg/kg), and rutin (30 mg/kg) were studied on alloxan-induced type 2 diabetic (AITD) and normoglycemic rats. In addition, oral glucose tolerance test (OGTT) and oral sucrose tolerance test (OSTT) were performed in normoglycemic rats. Molecular docking technique was used to conduct the computational study. Results: Bioassay-guided fractionation of EEAc afforded as major antihyperglycemic compound, rutin. EEAc attenuated postprandial hyperglycemia in acute test using AITD rats (331.5 mg/dL) carrying the glycemic levels to 149.2 mg/dL. Rutin after 2 h, attenuated postprandial hyperglycemia in an acute assay using AITD rats such as EEAc, with maximum effect (150.0 mg/dL) being seen at 4 h. The antihyperglycemic activities of EEAc and rutin were comparable with acarbose (151.3 mg/dL). In the subchronic assay on AITD rats, the EEAc and rutin showed a reduction of the blood glucose levels since the 1 st week of treatment, reaching levels similar to normoglycemic state (116.9 mg/kg) that stayed constant for the rest of the assay. OGTT and OSTT showed that EEAc and rutin significantly lowered blood glucose levels in normoglycemic rats at 2 h after a glucose or sucrose load such as acarbose. Computational molecular docking showed that rutin interacted with four amino acids residues in the enzyme α-glucosidase. Conclusion: The results suggest that rutin an α-glucosidase inhibitor was responsible in part of the antihyperglycemic activity of A. cherimola. Its in vivo antihyperglycemic activity is in good agreement with the traditional use of A. cherimola for the treatment of diabetes.",
author = "Fernando Calzada and Solares-Pascasio, {Jes{\'u}s Ivan} and Ordo{\~n}ez-Razo, {R. M.} and Claudia Velazquez and Elizabeth Barbosa and Normand Garc{\'i}a-Hern{\'a}ndez and David Mendez-Luna and Jos{\'e} Correa-Basurto",
year = "2017",
month = "1",
day = "1",
doi = "10.4103/0974-8490.199781",
language = "American English",
pages = "1--6",
journal = "Pharmacognosy Research",
issn = "0974-8490",
publisher = "Wolters Kluwer Medknow Publications",

}

Antihyperglycemic activity of the leaves from Annona cherimola miller and rutin on alloxan-induced diabetic rats. / Calzada, Fernando; Solares-Pascasio, Jesús Ivan; Ordoñez-Razo, R. M.; Velazquez, Claudia; Barbosa, Elizabeth; García-Hernández, Normand; Mendez-Luna, David; Correa-Basurto, José.

In: Pharmacognosy Research, 01.01.2017, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antihyperglycemic activity of the leaves from Annona cherimola miller and rutin on alloxan-induced diabetic rats

AU - Calzada, Fernando

AU - Solares-Pascasio, Jesús Ivan

AU - Ordoñez-Razo, R. M.

AU - Velazquez, Claudia

AU - Barbosa, Elizabeth

AU - García-Hernández, Normand

AU - Mendez-Luna, David

AU - Correa-Basurto, José

PY - 2017/1/1

Y1 - 2017/1/1

N2 - © 2017 Pharmacognosy Research | Published by Wolters Kluwer - Medknow. Background: Annona cherimola, known as 'chirimoya' has been reported in Mexican traditional medicine for the treatment of diabetes. Objective: The aims of the present study were to validate and assess the traditional use of A. cherimola as an antidiabetic agent. Materials and Methods: The ethanol extract from A. cherimola (300 mg/kg, EEAc), subsequent fractions (100 mg/kg), and rutin (30 mg/kg) were studied on alloxan-induced type 2 diabetic (AITD) and normoglycemic rats. In addition, oral glucose tolerance test (OGTT) and oral sucrose tolerance test (OSTT) were performed in normoglycemic rats. Molecular docking technique was used to conduct the computational study. Results: Bioassay-guided fractionation of EEAc afforded as major antihyperglycemic compound, rutin. EEAc attenuated postprandial hyperglycemia in acute test using AITD rats (331.5 mg/dL) carrying the glycemic levels to 149.2 mg/dL. Rutin after 2 h, attenuated postprandial hyperglycemia in an acute assay using AITD rats such as EEAc, with maximum effect (150.0 mg/dL) being seen at 4 h. The antihyperglycemic activities of EEAc and rutin were comparable with acarbose (151.3 mg/dL). In the subchronic assay on AITD rats, the EEAc and rutin showed a reduction of the blood glucose levels since the 1 st week of treatment, reaching levels similar to normoglycemic state (116.9 mg/kg) that stayed constant for the rest of the assay. OGTT and OSTT showed that EEAc and rutin significantly lowered blood glucose levels in normoglycemic rats at 2 h after a glucose or sucrose load such as acarbose. Computational molecular docking showed that rutin interacted with four amino acids residues in the enzyme α-glucosidase. Conclusion: The results suggest that rutin an α-glucosidase inhibitor was responsible in part of the antihyperglycemic activity of A. cherimola. Its in vivo antihyperglycemic activity is in good agreement with the traditional use of A. cherimola for the treatment of diabetes.

AB - © 2017 Pharmacognosy Research | Published by Wolters Kluwer - Medknow. Background: Annona cherimola, known as 'chirimoya' has been reported in Mexican traditional medicine for the treatment of diabetes. Objective: The aims of the present study were to validate and assess the traditional use of A. cherimola as an antidiabetic agent. Materials and Methods: The ethanol extract from A. cherimola (300 mg/kg, EEAc), subsequent fractions (100 mg/kg), and rutin (30 mg/kg) were studied on alloxan-induced type 2 diabetic (AITD) and normoglycemic rats. In addition, oral glucose tolerance test (OGTT) and oral sucrose tolerance test (OSTT) were performed in normoglycemic rats. Molecular docking technique was used to conduct the computational study. Results: Bioassay-guided fractionation of EEAc afforded as major antihyperglycemic compound, rutin. EEAc attenuated postprandial hyperglycemia in acute test using AITD rats (331.5 mg/dL) carrying the glycemic levels to 149.2 mg/dL. Rutin after 2 h, attenuated postprandial hyperglycemia in an acute assay using AITD rats such as EEAc, with maximum effect (150.0 mg/dL) being seen at 4 h. The antihyperglycemic activities of EEAc and rutin were comparable with acarbose (151.3 mg/dL). In the subchronic assay on AITD rats, the EEAc and rutin showed a reduction of the blood glucose levels since the 1 st week of treatment, reaching levels similar to normoglycemic state (116.9 mg/kg) that stayed constant for the rest of the assay. OGTT and OSTT showed that EEAc and rutin significantly lowered blood glucose levels in normoglycemic rats at 2 h after a glucose or sucrose load such as acarbose. Computational molecular docking showed that rutin interacted with four amino acids residues in the enzyme α-glucosidase. Conclusion: The results suggest that rutin an α-glucosidase inhibitor was responsible in part of the antihyperglycemic activity of A. cherimola. Its in vivo antihyperglycemic activity is in good agreement with the traditional use of A. cherimola for the treatment of diabetes.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85015748767&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85015748767&origin=inward

U2 - 10.4103/0974-8490.199781

DO - 10.4103/0974-8490.199781

M3 - Article

C2 - 28250646

SP - 1

EP - 6

JO - Pharmacognosy Research

JF - Pharmacognosy Research

SN - 0974-8490

ER -